About InVivoMAb anti-human TROP-2 The Pr1E11 monoclonal antibody reacts with human TROP-2, also known as TACSTD2, EGP-1, and GA733-1. TROP-2 is a type I transmembrane glycoprotein with high homology to TROP-1/EpCAM. TROP-2 spans the epithelial membrane surface and plays a role in embryonic development, cell self-renewal, proliferation, and transformation. TROP-2 is found on the surface of multiple normal epithelial tissues, including skin and oral mucosa. TROP-2 can promote tumor growth and its overexpression is common in many types of malignant epithelial tumors. A variety of human epithelial cancer cells are characterized by TROP-2 overexpression, including breast, lung, urothelial, gastric, colorectal, pancreatic, prostatic, cervical, head and neck, and ovarian carcinomas. InVivoMAb anti-human TROP-2 Specifications IsotypeMouse IgG1, κ Recommended Isotype Control(s)InVivoMAb mouse IgG1 isotype control, unknown specificity Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenPrimary human prostate cancer cells Reported ApplicationsWestern blot Immunohistochemistry (frozen) Flow cytometry FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<2EU/mg (<0.002EU/μg) Determined by LAL gel clotting assay Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtered ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein G Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze. Application ReferencesInVivoMAb anti-human TROP-2 (CLONE: Pr1E11)Ikeda M, Yamaguchi M, Kato K, Nakamura K, Shiina S, Ichikawa-Ando T, Misaka H, Myojo K, Nakamura K, Sugimoto Y, Hamada H (2015). "Pr1E11, a novel anti-TROP-2 antibody isolated by adenovirus-based antibody screening, recognizes a unique epitope" Biochem Biophys Res Commun 458(4):877-82. PubMedTROP-2 is a type Ⅰ transmembrane glycoprotein that is highly expressed in various epithelial cancer cells, and its increased expression correlates with poor prognosis. Although several anti-TROP-2 antibodies have been described, they were found unsuitable for antitumor therapy use in vivo as naked antibodies. In this study, we established a novel anti-TROP-2 antibody, designated Pr1E11, from mice immunized with primary prostate cancer cells. Antibody screening was based on the infection activity of Adv-LacZ-FZ33, which displays an immunoglobulin G binding domain in the adenoviral fiber protein. We found that Pr1E11 specifically binds to TROP-2 with high affinity and recognizes diverse epithelial cancer cell lines and primary pancreatic cancer tissues. Epitope analysis using TROP-2 deletion mutants revealed that binding site of Pr1E11 is a cysteine-rich domain, a unique epitope compared with other available anti-TROP-2 antibodies. In addition, Pr1E11 exhibited low internalization activity, which may make it suitable for naked antibody therapeutics. Our results suggest that Pr1E11 may stimulate different biological activities from other anti-TROP-2 antibodies based on its unique binding epitope, and is a potential candidate for naked antibody therapeutics for various epithelial cancer treatments.
